Centrymed

Centrymed is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology and autoimmune diseases. Established in 2017 in Hangzhou, China, with a U.S. entity founded in Maryland in 2016, the company operates an integrated research and development ecosystem across both countries. The company was founded by Dr. Zuoxiang Xiao, who serves as Chairman and CEO. Dr. Xiao has over three decades of experience in oncology and immunopathology, including research positions at the Johns Hopkins School of Medicine and the U.S. National Cancer Institute (NCI). His scientific contributions include creating the first murine model for non-small cell squamous carcinoma and discovering the potential of zinc chelators to inhibit HIV replication.

The company's business model combines in-house development of proprietary drugs with a strategy that includes technology platform licensing and co-development partnerships to generate revenue at various stages. Centrymed is backed by significant venture capital, having completed multiple funding rounds up to Series C, raising hundreds of millions of RMB from investors such as Cybernaut Investment, Gortune Investment, and Tigermed. The firm targets unmet medical needs by developing first-in-class and best-in-class biologics. Its product pipeline includes over 20 antibody programs in monoclonal, bispecific, and trispecific formats. Key assets that have entered clinical trials include SMET12, a bispecific antibody targeting EGFR and CD3 for solid tumors, and DNV3, a LAG-3 antibody for melanoma. Several of its drug candidates have received Investigational New Drug (IND) clearance from both the U.S. FDA and China's NMPA.

Centrymed has developed four proprietary technology platforms to drive its pipeline: a fully human IgM antibody library for discovering new antibody sequences, the H-BiTE platform for T-cell engaging bispecific antibodies, the Pro-BiTE platform for tumor-specific activation, and a multifunctional T-cell engager platform. These technologies enable the creation of therapies designed for high specificity and safety, aiming to overcome the challenges of treating solid tumors. The company has received numerous accolades, including being named a "Hangzhou Future Unicorn Company" and winning first prize in the China Innovation & Entrepreneurship Competition in Zhejiang.

Keywords: antibody drug development, oncology therapeutics, autoimmune diseases, bispecific antibodies, clinical-stage biotech, T-cell engager, monoclonal antibodies, immunotherapy, cancer treatment, Hangzhou biopharma, antibody discovery platform, solid tumors, LAG-3 antibody, EGFRxCD3, venture capital backed, preclinical, clinical trials, biologics, drug discovery, biopharmaceutical, first-in-class, orphan drugs, molecular targeted therapy, China biotech, US biotech